Human Gremlin 1 chimeric vaccine for treating liver fibrosis, and applications thereof

A chimeric vaccine, hepatitis B technology, applied in the field of human Gremlin 1 chimeric vaccine for the treatment of liver fibrosis, can solve the problems of poor application prospects, complicated preparation methods, high cost, etc. The effect of reducing the grade of fibrosis and reducing the content of Hyp

Inactive Publication Date: 2015-10-21
THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, from the perspective of clinical application, the above methods all have outstanding shortcomings such as complicated preparation methods, high costs, and inconvenient use, and the application prospects are not good.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human Gremlin 1 chimeric vaccine for treating liver fibrosis, and applications thereof
  • Human Gremlin 1 chimeric vaccine for treating liver fibrosis, and applications thereof
  • Human Gremlin 1 chimeric vaccine for treating liver fibrosis, and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0039] The invention provides a human Gremlin 1 chimeric vaccine for treating liver fibrosis, successfully inserting the B cell epitope of human Gremlin 1 into the c / e1 epitope of hepatitis B core antigen, and constructing a human that can be assembled into hepatitis B core-like particles Gremlin 1 chimeric vaccine. The vaccine can still stimulate the body to produce high-titer neutralizing antibodies against human Gremlin 1 without the aid of an adjuvant. According to the chicken chorioallantoic membrane experiment, the anti-human Gremlin 1 neutralizing antibody can significantly inhibit the angiogenesis mediated by human Gremlin 1. The mice immunized with the vaccine were treated with CCl 4 The degree of liver fibrosis after induction was significantly reduced. In further research, we found that immunization with human Gremlin 1 chimeric vaccine can significantly reduce the damage of liver function (ALT and AST) in mice and inhibit the activation of hepatic stellate cells ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a human Gremlin 1 chimeric vaccine for treating liver fibrosis, and applications thereof, wherein human Gremlin 1 B-cell epitope is inserted into the c/e1 epitope of hepatitis B virus core antigen to construct the human Gremlin 1 chimeric vaccine capable of assembling hepatitis B virus core particles. According to the present invention, the chimeric vaccine can stimulate the body to produce high-titer anti-human Gremlin 1 neutralizing antibody without adjuvant assisting; with the application of the chimeric vaccine to immunize mice, the mice are induced to produce anti-Gremlin 1 antibodies so as to neutralize the cytokine Gremlin 1 over-expressed during the CCl4-induced liver fibrosis process and inhibit the promoting effect of the cytokine Gremlin 1 in the liver fibrosis development process, such that the liver fibrosis process develop is inhibited to a certain extent; and the results confirm that the CCl4-induced mouse liver fibrosis can be significantly inhibited after the Gremlin 1 recombinant protein vaccine is used to immunize mice, and the Gremlin 1 vaccine is expected to be a simple, safe, and effective new method for prevention and treatment of liver fibrosis.

Description

technical field [0001] The invention belongs to the field of drugs for treating liver fibrosis, and in particular relates to a human Gremlin 1 chimeric vaccine for treating liver fibrosis and its application. Background technique [0002] Liver fibrosis is the pathological process necessary for a variety of chronic liver diseases to develop into cirrhosis, and is the most important factor determining the prognosis of chronic liver diseases. At present, most chronic liver diseases lack effective etiological treatment, and studies have confirmed that liver fibrosis can continue to progress after the etiology of some liver diseases is removed, so the occurrence and development of liver fibrosis can be blocked or delayed, so as to prevent the progression to liver cirrhosis. One of the main approaches in the treatment of chronic liver disease. However, there are no effective anti-hepatic fibrosis drugs or measures at present. Exploring safe and effective anti-hepatic fibrosis me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P1/16
Inventor 郝志明李爽李倩蒋会平苏厚强张雪婷
Owner THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap